Pfizer’s Lyrica Will Undergo Phase IV Vision, Nerve Impairment Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer also commits to a post-marketing study of pregabalin’s propensity to induce CYP-enzyme metabolism. Lyrica is undergoing controlled substance scheduling by DEA. The European Medicines Agency says that study data suggest pregabalin is not a “prototypic” risk for abuse when compared to diazepam.
You may also be interested in...
Lyrica's DEA Scheduling Will Not Hold Back Sales, Pfizer Says
Pfizer CEO McKinnell says "the level of scheduling we're anticipating...should not have a significant impact on our opportunity" with Lyrica. Pfizer will work to lift DEA's scheduling for Lyrica, Senior VP Feczko says.
Lyrica's DEA Scheduling Will Not Hold Back Sales, Pfizer Says
Pfizer CEO McKinnell says "the level of scheduling we're anticipating...should not have a significant impact on our opportunity" with Lyrica. Pfizer will work to lift DEA's scheduling for Lyrica, Senior VP Feczko says.
Pfizer Lyrica Undergoing Controlled Substance Scheduling At DEA
FDA clears pregabalin for management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. The Neurontin follow-on compound remains "approvable" for the adjunctive treatment of partial seizures in adults with epilepsy.